I am excited to join Rutgers Cancer Institute of New Jersey. Rutgers Cancer Institute – the only National Cancer Institute-designated Comprehensive Cancer Center in NJ – is at the forefront of cancer research, offering state-of-the-art treatment to patients. As a medical oncologist, I specialize in hematologic malignancies including B and T cell lymphomas, plasma cell dyscrasias, as well as cellular therapies such as chimeric antigen receptor T-cells (CAR-Ts).
Prior to medical school, I attended Johns Hopkins University where I earned a PhD in Biology, studying the role of Wnts in peripheral nervous system development, after which I completed a post-doctoral fellowship studying the effect of anesthesia on neuronal development. My medical training was at Columbia University College of Physicians and Surgeons, followed by a residency in internal medicine at New York Presbyterian Hospital- Columbia University and a 3-year fellowship in hematology and medical oncology at Columbia University Irving Medical Center.
During fellowship, I explored the effects of combination epigenetic drugs including a novel agent, a histone acetyltransferase activator, in enhancing immunogenicity in germinal center derived lymphomas. For this work, I was awarded the 2022 American Society of Hematology Research Training Award for Fellows (ASH-RTAF) and the 2023 American Society of Clinical Oncology Young Investigator Award (ASCO YIA).
I look forward to being at Rutgers Cancer Institute, working with a dedicated team of clinicians and researchers, where I will continue my research while caring for my patients. I am well aware that a cancer diagnosis can be terrifying and overwhelming. I strive to provide the highest standards of care with empathy and compassion.
Accepted Health Plan information is only as accurate as the most current
information submitted. Prior to your appointment, it is advisable to verify
with a physician office that they are still a participating provider.
